Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
September 01 2022 - 7:00AM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that Christopher Kirk, PhD, Co-founder, President and
Chief Scientific Officer, will participate in three upcoming
investor conferences in September.
Presentation Details:
Event: 2022 Wells Fargo Healthcare Conference
Location: Boston, MA Date/Time: Thursday, September
8, 2022, at 1:20 PM ET Format: Fireside Chat
Event: H.C. Wainwright 24th Annual Global Investment
Conference Location: New York, NY Date/Time: Tuesday,
September 13, 2022, at 11:30 AM ET Format: Podium
Presentation
Event: Morgan Stanley 20th Annual Global Healthcare
Conference Location: New York, NY Date/Time:
Wednesday, September 14, 2022, at 9:10 AM ET Format:
Fireside Chat
Webcasts from the presentations will be available on the “Events
& Presentations” section of the Company’s website at
www.kezarlifesciences.com. Following the events, archived webcasts
will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220901005005/en/
Investor Contact Gitanjali Jain Vice President, Investor
Relations and External Affairs 650-269-7523 gjain@kezarbio.com
Media Contact Liza Sullivan Argot Partners 212-600-1902
kezar@argotpartners.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Apr 2024 to May 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From May 2023 to May 2024